The aim of this study is to evaluate the transaminases capacity in predicting the adverse outcomes of preeclampsia.
This study was carried out among women hospitalized in Department of Obstetrics and Gynecology and intensive care unit at maternity university hospital between January 2013 and June 2015. We have compared the group of eclampsia with preeclampsia control group, each case (eclamptic woman) was matched to a control (preeclamptic woman), a ratio of 1/1. Transaminases levels were compared in the two groups (cases and controls).
58 cases of eclampsia were observed during the study period, corresponding to a rate of 7.9 per 10,000 births. Transaminases levels were higher among eclamptic women compared to women with preeclampsia, respectively 107.10 U/L and 28.2 U/L for ALT, and 171.75 U/L and 30.12 U/L for AST (p = 0.01 and p = 0.008).
ALT area under the ROC curve was 0.718 (CI 95%: 0.62-0.81). For a sensitivity of 74% and a specificity of 66%, the best threshold value was 57 U/L. While for AST the area under the ROC curve was 0.716 (CI 95%: 0.61-0.82), the best threshold value was 59 U/l, with a sensitivity of 76% and a specificity of 57%.
Transaminases levels were significantly higher during eclampsia compared with preeclampsia. This is a clinically useful way to predict the adverse outcomes of preeclampsia. However, a prospective study is necessary to develop a clinical prediction model of eclampsia.